Evidence map›Paper›PMID 34944897›Full record

ArticleCancers2021

RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.

Emmy Boerrigter, Guillemette E Benoist, Inge M van Oort, Gerald W Verhaegh, Anton F J de Haan, Onno van Hooij, Levi Groen, Frank Smit, Irma M Oving, Pieter de Mol and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels ofInternational journal of molecular sciences · 2022
    Article
  5. The Androgen Regulated lncRNANon-coding RNA · 2022
    Article
  6. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Emmy BoerrigterRadboud University Medical Center, Department of Pharmacy, Radboud Institute for Health Sciences, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-3041-6774
Guillemette E BenoistRadboud University Medical Center, Department of Pharmacy, Radboud Institute for Health Sciences, 6525 GA Nijmegen, The Netherlands.
Inge M van OortRadboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
Gerald W VerhaeghRadboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-0227-2280
Anton F J de HaanRadboud University Medical Center, Department for Health Evidence, Biostatistics, 6525 GA Nijmegen, The Netherlands.
Onno van HooijRadboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-1258-2146
Levi GroenRadboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
Frank SmitMDxHealth, 6534 AT Nijmegen, The Netherlands.
Irma M OvingDepartment of Medical Oncology, Ziekenhuisgroep Twente, 7609 PP Almelo, The Netherlands.
Pieter de MolDepartment of Medical Oncology, Gelderse Vallei Hospital, 6716 RP Ede, The Netherlands.
Tineke J SmildeDepartment of Medical Oncology, Jeroen Bosch Hospital, 5223 GZ 's-Hertogenbosch, The Netherlands.ORCID 0000-0002-4196-3765
Diederik M SomfordDepartment of Urology, Canisius Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands.ORCID 0000-0002-5277-6586
Paul HambergDepartment of Medical Oncology, Franciscus Gasthuis & Vlietland, 3045 PM Rotterdam, The Netherlands.
Vincent O DezentjéDepartment of Medical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
Niven MehraRadboud University Medical Center, Department of Medical Oncology, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0002-4794-1831
Nielka P van ErpRadboud University Medical Center, Department of Pharmacy, Radboud Institute for Health Sciences, 6525 GA Nijmegen, The Netherlands.
Jack A SchalkenRadboud University Medical Center, Department of Urology, Radboud Institute for Molecular Life Sciences, 6525 GA Nijmegen, The Netherlands.
Radboud University Nijmegen · NLCanisius-Wilhelmina Ziekenhuis · NLJeroen Bosch Ziekenhuis · NLMDxHealth (Netherlands) · NLSint Franciscus Gasthuis · NLThe Netherlands Cancer Institute · NLZiekenhuis Gelderse Vallei · NLZiekenhuis Groep Twente · NL

Funding

Astellas Pharma BV not applicableJanssen Cilag BV not applicableNetherlands Organisation for Health Research and Development 836041013
6 · The paper itself

Abstract

Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term survivors from long-term survivors, shortly after treatment initiation. Thereto, the added value of early RNA biomarkers on predicting progression-free survival (PFS) and overall survival (OS) were explored. The RNA biomarkers:

Indexed as

abiraterone acetatebiomarkerscastration-resistant prostate cancerenzalutamideliquid biopsyRNAsurvival

Identifiers

PMID34944897
PMCPMC8699291
OpenAlexW4200309046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.